المؤلفون: Bristol, Andrew

المصدر: NZGrower, Aug 2023; v.78 n.7:p.10-11
NZ grower
New Zealand grower

URL الوصول: https://ndhadeliver.natlib.govt.nz/delivery/DeliveryManagerServlet?dps_pid=IE88366659

المؤلفون: Fisher, Elaine, Troughton, Jamie, Bristol, Andrew

المصدر: Orchardist, Aug 2023; v.96 n.7:p.26-29

URL الوصول: https://ndhadeliver.natlib.govt.nz/delivery/DeliveryManagerServlet?dps_pid=IE88366723

المؤلفون: Daniel, Kathryne J., Smith, Joshua R., Ballmer, Stefan, Bristol, Warren, Driggers, Jennifer C., Effler, Anamaria, Evans, Matthew, Hoover, Joseph, Kuns, Kevin, Landry, Michael, Lovelace, Geoffrey, Lukinbeal, Chris, Mandic, Vuk, Pham, Kiet, Read, Jocelyn, Russell, Joshua B., Schiettekatte, Francois, Schofield, Robert M. S., Scholz, Christopher A., Shoemaker, David H., Sledge, Piper, Strunk, Amber

مصطلحات موضوعية: Physics - Instrumentation and Detectors, Astrophysics - Instrumentation and Methods for Astrophysics

URL الوصول: http://arxiv.org/abs/2410.00293

المؤلفون: Yan Yao (ORCID 0009-0009-7679-295X), Carleigh Bristol Slater (ORCID 0009-0001-6310-139X)

المصدر: Language Teaching Research Quarterly. 2024 40:94-112.

Peer Reviewed: Y

Page Count: 19

Descriptors: Language Teachers, Teacher Attitudes, Professional Identity, Second Language Instruction, Second Language Learning, Self Concept, Foreign Countries, Personal Autonomy, Private Education, Sociocultural Patterns, Barriers, Instructional Effectiveness, Language Proficiency, Learning Motivation, Teacher Student Relationship, Teacher Role, Faculty Development, Teaching Conditions

مصطلحات جغرافية: China

المؤلفون: Bristol-Myers Squibb

المصدر: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation

Other URLs: https://www.janssen.com/clinical-trials/transparency

المؤلفون: North Bristol NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust, University College London Hospitals, NHS Greater Glasgow and Clyde

المصدر: A Single Blinded, IDEAL Stage 3, Multi-centre, Randomised Controlled Trial to Assess NeuroSAFE Robotic Assisted Radical Prostatectomy (RARP) Vs Standard Robotic Assisted Radical Prostatectomy (RARP) in Men with Prostate Cancer
https://doi.org/10.6084/m9.figshare.27054979.v1
Beyer B, Schlomm T, Tennstedt P, Boehm K, Adam M, Schiffmann J, Sauter G, Wittmer C, Steuber T, Graefen M, Huland H, Haese A. A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomy. Eur Urol. 2014 Jul;66(1):138-44. doi: 10.1016/j.eururo.2013.12.014. Epub 2013 Dec 24.
Vasdev N, Agarwal S, Rai BP, Soosainathan A, Shaw G, Chang S, Prasad V, Mohan-S G, Adshead JM. Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series. Curr Urol. 2016 May;9(2):93-103. doi: 10.1159/000442860. Epub 2016 May 20.
Dinneen E, Grierson J, Almeida-Magana R, Clow R, Haider A, Allen C, Heffernan-Ho D, Freeman A, Briggs T, Nathan S, Mallett S, Brew-Graves C, Muirhead N, Williams NR, Pizzo E, Persad R, Aning J, Johnson L, Oxley J, Oakley N, Morgan S, Tahir F, Ahmad I, Dutto L, Salmond JM, Kelkar A, Kelly J, Shaw G. NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer. Trials. 2022 Jul 22;23(1):584. doi: 10.1186/s13063-022-06421-7.
Almeida-Magana R, Maroof H, Grierson J, Clow R, Dinneen E, Al-Hammouri T, Muirhead N, Brew-Graves C, Kelly J, Shaw G. E-Consent-a guide to maintain recruitment in clinical trials during the COVID-19 pandemic. Trials. 2022 May 12;23(1):388. doi: 10.1186/s13063-022-06333-6.
Dinneen E, Haider A, Grierson J, Freeman A, Oxley J, Briggs T, Nathan S, Williams NR, Brew-Graves C, Persad R, Aning J, Jameson C, Ratynska M, Ben-Salha I, Ball R, Clow R, Allen C, Heffernan-Ho D, Kelly J, Shaw G. NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial. BJU Int. 2021 Jun;127(6):676-686. doi: 10.1111/bju.15256. Epub 2021 Mar 29.
Dinneen E, Haider A, Allen C, Freeman A, Briggs T, Nathan S, Brew-Graves C, Grierson J, Williams NR, Persad R, Oakley N, Adshead JM, Huland H, Haese A, Shaw G. NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study. BMJ Open. 2019 Jun 11;9(6):e028132. doi: 10.1136/bmjopen-2018-028132.

Other URLs: https://pubmed.ncbi.nlm.nih.gov/35869497/

المؤلفون: Bristol-Myers Squibb

المصدر: Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul;169:93-102. doi: 10.1016/j.ejca.2022.03.026. Epub 2022 May 5.

المؤلفون: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.

المصدر: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.

المؤلفون: Bristol-Myers Squibb Services Unlimited Company

المصدر: A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis

Other URLs: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

المؤلفون: The Fortune Society, University of Bristol, National Institute on Minority Health and Health Disparities (NIMHD), Cepheid

المصدر: Leveraging Community Health Workers to Improve COVID-19 Testing and Mitigation Among Criminal Justice-involved Individuals Accessing a Corrections-focused Community-based Organization

المؤلفون: Bristol-Myers Squibb

المساهمون: Aaron R. Mangold, Principal Investigator

المصدر: Deucravacitinib (BMS-986165) in the Treatment of Lichen Planopilaris

المؤلفون: Celgene, Bristol-Myers Squibb

المساهمون: Mikkael Sekeres, MD, Professor

المصدر: A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

المؤلفون: Bristol-Myers Squibb, Lymphoma Study Association, University of Leipzig

المصدر: Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma

المؤلفون: Bristol-Myers Squibb

المساهمون: Xiao X. Wei, MD, Sponsor Investigator

المصدر: A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

المؤلفون: Bristol-Myers Squibb, Exelixis

المساهمون: Kimberly Perez, MD, Principal Investigator

المصدر: Phase II Trial of Cabozantinib in Combination With Nivolumab for Advanced Carcinoid Tumors

المؤلفون: Bristol-Myers Squibb

المصدر: AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

المؤلفون: Bristol-Myers Squibb

المساهمون: Candace Hillary Feldman, MD, Assistant Professor

المصدر: Achieving Equity in Inflammatory Arthritis Care: an Adaptive Trial to Understand and Address Social Determinants of Health

المؤلفون: Gilead Sciences, Novartis, Bristol-Myers Squibb

المصدر: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.

المؤلفون: Bristol-Myers Squibb

المصدر: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

المؤلفون: Bristol-Myers Squibb, Janssen Scientific Affairs, LLC, Pfizer

المصدر: Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):751-758. doi: 10.1038/s41391-022-00590-x. Epub 2022 Sep 13.
Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 Mar;127:67-75. doi: 10.1016/j.ejca.2019.12.027. Epub 2020 Jan 24.